Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IASO206 in Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07585071Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
01
Overview
Phase 1, open-label, single-arm trial of IASO 206 in autoimmune hemolytic anemia (AIHA) and Evans syndrome, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Incidence and severity of adverse events up to 3 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
IASO 206
03
Conditions
autoimmune hemolytic anemia (AIHA)Evans syndrome
Beyond the preview
Go deeper on NCT07585071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07585071.